Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer
Source: SeekingAlpha
2025-06-17 09:44:23 ET
More on Regeneron Pharmaceuticals, 23andMe
- Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript
- Itepekimab Failure A Setback For Sanofi And Regeneron
- Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
- 23andMe sold to non-profit headed by co-founder Anne Wojcicki
- Sens. Sanders, King introduce bill to end prescription drug advertising
Read the full article on Seeking Alpha
For further details see:
Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer
Regeneron Pharmaceuticals Inc.
NASDAQ: REGN
REGN Trading
-1.59% G/L:
$742.885 Last:
150,713 Volume:
$754.55 Open:
REGN Latest News
March 12, 2026 04:04:00 am
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
REGN Stock Data
$80,621,924,056
100,116,656
N/A
714
N/A
Biotechnology & Life Sciences
Healthcare
US
Tarrytown
